NVO — All updates

5 entries loaded; 0 direction changes

Filter loaded records
The Investor's PodcastPublished 2026-10-31
“S&P Global (SPGI), Novo Nordisk (NVO), Deckers (DECK) | Stock Analysis & Valuation (TIP857)”
$NVOBullish
AI summary · Bullish on NVO: at ~12x forward earnings—half the S&P's mid-20s multiple and vs Eli Lilly at 24x—most bad news is baked in. Base case is mid-single-digit earnings growth plus a 4.5% dividend yield, for 8-9% annual returns over five years (max 10% incl dividend); if oral obesity drugs and phase-three amiritin succeed by 2028, returns could be 18-22% on a re-rating. He doesn't expect a double next year and cites Medicare pricing, patent expiries/generics, guidance down to 2030 and value-trap/innovation risk.

So my pick today is one of those companies which two years ago was the most valuable company in Europe. And pretty much everybody owned it. I don't know whether you owned it Stig, but pretty much a lot of people, a lot of ETFs, a lot of funds owned this company.

The analysts really loved it. But today that stock is down 40%. And from its 52- week high and it's trading roughly around 12 times forward earnings and basically everybody's saying parties over here.

Parkev Tatevosian, CFAPublished 2026-09-26
“Novo Nordisk Gives Uninspiring Outlook”
$NVOBullish
AI summary · NVO is a buy despite lowered valuation and conviction; significant upside remains.

Novo Nordisk informed investors that it will increase its revenue at a medium single-digit rate through 2030. It also stated that it will increase the number of patients it serves to more than 60 million, up from about 46.5 million currently.

Despite these strong expectations, investors were not impressed with Novo Nordisk's performance. The stock has fallen by more than 25% since the beginning of 2026. So, does all this make Novo a buying opportunity when its price drops?

Schwab NetworkPublished 2026-09-21
“Iran & China at Forefront of Trading Week, Critical Metals Rally & NVO Slides”
$NVOBearish
AI summary · NVO shares are under pressure as the market finds its strategic plan insufficiently bold or fast, though technical support exists at $40.

Now let's talk about Novo, formerly known as Novo Nordisk. The company's shares are under pressure this morning. The market appears to be dissatisfied with the plan revealed by Novo regarding its strategy for the next phase.

It is clear that they saw a large demand for their weight loss drug, at least in its early stages. But now, competition has entered this field and captured part of their market share.

That's the earliest record
All updates for other tickers
Follow $NVO30-day free trial
Start trial